Furthermore, PARP-1 inhibition leads to a significant decrease in the intravasation capacity of Erg-expressing cancer cells, which is more proof of the reduced ability of ETS-expressing cells to commit invasion under PARP-1 inhibition. The gene discussed is PARP1; the disease is cancer.